drugset / Trial / NCT06745557
Phase III Study with an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
RandomizedSingle-groupOpen-labelTreatment
Summary
This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as compared to split-thickness skin.
Timeline
- Start
- 2024-12-13
- Primary completion
- 2026-12-31
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | denovoSkin(TM) | Cell therapy | — | — |
Indications
No indication recorded.